Investors hammered Cooper Companies (COO) on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations, leading to a guidance cut.
Specifically, the CooperVision segment — which sells contact lenses — missed expectations by 4.5%, William Blair **** yst Steven Lichtman said in a report. The miss was due to destocking. Further, the company opted against selling its CooperSurgical business following a strategic review.
"The 'no sale' is a surprise after management highlighted prospective buyers on the last earnings call," he said. "With CVI (CooperVision) results also disappointing, the stock moves back into the penalty box."
On today's stock market, Cooper Companies shares toppled 14.7%, closing at 54.17. Shares are already trading well below their key moving averages, IBD MarketSurge charts show.
Cooper said it couldn't sell the surgical division due to competition for its implantable contraceptive, Paragard, an intrauterine device. In June, Organon (OGN) licensed Miudella, a rival to Cooper's non-hormonal IUD. Cooper is also facing fertility litigation, BofA Securities **** yst Travis Steed said in a note to clients.

#Companies #expectations #investors #wall